Evidence map›Paper›PMID 32548784›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2020

Effects of 2',6'-dihydroxy-4'-methoxydihidrochalcone on innate inflammatory response.

Murilo Luiz Cerutti, Larissa Benvenutti, Roberta Nunes, Silvia Ramos da Silva, Sara Cristiane Barauna, Márcia Maria de Souza, Ângela Malheiros, Letícia Lacava, Nara Lins Meira Quintão, José Roberto Santin

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Murilo Luiz CeruttiPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade do Vale do Itajaí-UNIVALI, Rua Uruguai, Itajaí, Santa Catarina, 458, Brazil.
Larissa BenvenuttiPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade do Vale do Itajaí-UNIVALI, Rua Uruguai, Itajaí, Santa Catarina, 458, Brazil.
Roberta NunesPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade do Vale do Itajaí-UNIVALI, Rua Uruguai, Itajaí, Santa Catarina, 458, Brazil.
Silvia Ramos da SilvaPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade do Vale do Itajaí-UNIVALI, Rua Uruguai, Itajaí, Santa Catarina, 458, Brazil.
Sara Cristiane BaraunaDepartment of Natural Sciences, Center for Exact and Natural Sciences, Universidade Regional de Blumenau, Blumenau, Santa Catarina, Brazil.
Márcia Maria de SouzaPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade do Vale do Itajaí-UNIVALI, Rua Uruguai, Itajaí, Santa Catarina, 458, Brazil.
Ângela MalheirosPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade do Vale do Itajaí-UNIVALI, Rua Uruguai, Itajaí, Santa Catarina, 458, Brazil.
Letícia LacavaSchool of Health Sciences, Pharmacy Course, Universidade do Vale do Itajaí, Itajaí, Santa Catarina, Brazil.
Nara Lins Meira QuintãoPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade do Vale do Itajaí-UNIVALI, Rua Uruguai, Itajaí, Santa Catarina, 458, Brazil.
José Roberto SantinPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade do Vale do Itajaí-UNIVALI, Rua Uruguai, Itajaí, Santa Catarina, 458, Brazil. jrs.santin@univali.br.
Universidade do Vale do Itajaí · BRUniversidade Regional de Blumenau · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chalcones present potential therapeutic activities reported on literature, which led us to evaluate the anti-inflammatory effects and the acute toxicity of 2',6'-dihydroxy-4'-methoxydihydrochalcone (DHMDC) using in vitro and in vivo models. The anti-inflammatory activity was firstly in vitro investigated using macrophages (RAW 264.7) and neutrophils previously treated with DHMCD activated with lipopolysaccharide (LPS). Nitrite, IL-1β, and TNF levels were measured in the macrophage culture supernatant, and the adhesion molecule expression (CD62L, CD49D, and CD18) was evaluated in neutrophils. Then, carrageenan-induced inflammation was performed in the subcutaneous tissue of male Swiss mice. Leukocyte migration and histological analysis were performed in the pouches. Toxicological studies were carried out on female Swiss mice (600 mg/kg) through biochemical parameters and histopathological analysis. In vitro, the DHMCD significantly reduced the IL-1β, TNF, and nitrite levels. The DHMCD was also able to modulate the percentage of positive neutrophils for CD62L, without modifying the expression of CD18 or CD49d. In vivo, DHMCD (3 mg/kg, p.o.) significantly reduced neutrophil migration to inflammatory exudate and subcutaneous tissue. No evidence of toxic effect was observed considering the biochemical parameters and histopathological analysis of liver and kidney. Together, the obtained data shows that DHMCD presents anti-inflammatory activity by modulating the macrophage inflammatory protein secretion and also by blocking the CD62L cleavage in neutrophils. Furthermore, there was not any evidence of toxic effect in acute toxicological analysis.

Indexed as

AnimalsAnti-Inflammatory AgentsChalconesDisease Models, AnimalFemaleInflammationInflammation MediatorsInterleukin-1betaL-SelectinMacrophage ActivationMacrophagesMaleMiceNeutrophil ActivationNeutrophil InfiltrationNeutrophils2',6'-dihydroxy-4'-methoxydihydrochalconeAnti-Inflammatory AgentsChalconesIL1B protein, mouseInflammation MediatorsInterleukin-1betaL-SelectinNitric OxideTnf protein, mouseTumor Necrosis Factor-alphaAdhesion moleculesChalconeInflammationMacrophagesMiceNeutrophil

Identifiers

PMID32548784
OpenAlexW3034433542

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.